Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

CME/CPD

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Hepatitis C

Author index
Gut Apr 2005, 54 (suppl 2) a118-a134;
PTH-068 The use of Oesophageal Capsule Endoscopy in Patients with Haemophilia; Experience from a Tertiary Centre
Y L Ang, A Koulaouzidis, S Douglas, J N Plevris

Gut Jun 2013, 62 (Suppl 1) A238-A239; DOI: 10.1136/gutjnl-2013-304907.555
P51 Interferon-induced fatigue in hepatitis C infected patients is associated with increased expression of indoleamine 2,3-dioxygenase in peripheral blood mononuclear cells
M Gess, D Forton, A M Myint

Gut Sep 2011, 60 (Suppl 2) A24; DOI: 10.1136/gutjnl-2011-300857a.51
P50 Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic hepatitis C infection: evidence for genotype-specific modulation of lipid pathways
S Bridge, D Sheridan, D Felmlee, M Crossey, H Thomas, S Taylor-Robinson, G Toms, D Neely, M Bassendine

Gut Sep 2011, 60 (Suppl 2) A24; DOI: 10.1136/gutjnl-2011-300857a.50
P57 The IL28B gene SNP rs12979860 CC haplotype, predictor of response to treatment in chronic HCV infection, is associated to high numbers of CD56bright NK cells, low numbers of CD3-CD56-CD16+ NK cells and low HCV-specific IL-10 production
I Carey, M Bruce, A Mendes, A Scalori, D Joshi, K Agarwal, G Mieli-Vergani, D Vergani

Gut Sep 2011, 60 (Suppl 2) A26-A27; DOI: 10.1136/gutjnl-2011-300857a.57
P58 Genetic, virological and immunological pre-treatment predictors of therapy response to Peg-IFN/ribavirin in children with chronic hepatitis C
I Carey, M Bruce, S Bansal, S Tizzard, D Joshi, D Vergani, G Mieli-Vergani

Gut Sep 2011, 60 (Suppl 2) A27; DOI: 10.1136/gutjnl-2011-300857a.58
OC-081 Defining Cirrhosis with Fibroscan for entry to Hepatocellular Carcinoma Surveillance in Chronic Hepatitis C: a UK Cost Effectiveness Analysis
C Canavan, K Corey, C Hur

Gut Jun 2013, 62 (Suppl 1) A35; DOI: 10.1136/gutjnl-2013-304907.080
P68 PACIFIC: a phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection
S Tanwar, M Wright, G Foster, S Ryder, P Mills, M Cramp, J Parkes, W Rosenberg

Gut Sep 2010, 59 (Suppl 2) A38-A39; DOI: 10.1136/gut.2010.223362.94
P75 Influence of vitamin D supplementation on outcome in the treatment of chronic hepatitis C
P Southern, P El-Sayed, L Fenton, K Forrester, S Morrea

Gut Sep 2010, 59 (Suppl 2) A41; DOI: 10.1136/gut.2010.223362.101
P81 Psychiatric side effects of antiviral therapy with pegylated interferon and ribavirin are associated with poor response in children with chronic hepatitis C
I Carey, C Pariante, S Bansal, P Subramaniam, S Tizzard, D Vergani, G Mieli-Vergani

Gut Sep 2010, 59 (Suppl 2) A43-A44; DOI: 10.1136/gut.2010.223362.107

Pages